Therefore, in melanoma model the therapy with P2Et or P2Et plus αPD-L1 induces a significant increase in the number of tumor-infiltrating CD45+ cells per mg of tissue, compared to PBS or αPD-L1 groups (Figure 5A). The gene discussed is PTPRC; the disease is melanoma.